Clinical Trial Details
Braintumor Website

[Information provided by:, which provides patients, family members, and members of the public easy and free access to information on clinical studies for a wide range of diseases and conditions.]

NCT02252523 : Dexmedetomidine-based Sedation in Neurocritical Care Patients
PhasePhase 2
AgesMin: 18 Years Max: N/A
Inclusion Criteria:

- Brain-injured patients (traumatic brain injury, subarachnoid or intracerebral
hemorrhage, postoperative neurosurgical procedure)

- Older than 18 years

- Requiring sedation and analgesia for mechanical ventilation longer than 48 hours

- Written informed consent obtained from patients next-of-kin, before study enrollment

- Depending on the absence or presence of lesion which may increase intracranial
pressure, patients will be included in the "light to moderate" sedation subgroup or
in the "deep" sedation subgroup

Exclusion Criteria:

- - Heart rate < 45 bpm,

- Uncontrolled shock or cardiac failure,

- High-grade AV block,

- Acute ischemic neurological injury,

- Severe liver failure,

- Drug overdose and prior enrollment in a trial with any experimental drug in the last
30 days,

- Need for ongoing neuromuscular blockade except for tracheal intubation,

- Pregnancy/lactation,

- Known allergic reaction to dexmedetomidine,

- Uncontrolled diabetes.
LinksPermanent Link to THIS page:      |      Link to official listing

Home | Brain Tumor Guide | FAQs | Find A Treatment
Noteworthy Treatments | News | Virtual Trial | Videos | Novocure Optune® | Newsletter
Donations | Brain Tumor Centers | Survivor Stories | Temodar®
Fundraising For Research | Unsubscribe | Contact Us

Copyright (c) 1993 - 2020 by:
The Musella Foundation For Brain Tumor Research & Information, Inc
1100 Peninsula Blvd
Hewlett, NY 11557